Live at RESI Boston – September 17 | Westin Copley Place
By Momo Yamamoto, Senior Investor Research Analyst, LSN
For many early-stage life science companies, partnering with a major pharmaceutical firm can be a transformative milestone. Beyond capital, Big Pharma brings global reach, regulatory know-how, and commercialization muscle, opening doors that would otherwise be out of reach. But breaking through the noise and earning that opportunity requires more than a strong pitch deck.
The “Partnering with Big Pharma” panel at RESI Boston will offer a rare, inside look at how business development and licensing leaders identify and evaluate emerging innovation, including therapeutics and enabling technologies.
What Does Big Pharma Look For?
This 50-minute session will dive into the key criteria pharma decision-makers use to vet early-stage companies. From the strength of the data package and differentiation in a crowded landscape to alignment with therapeutic priorities and unmet need, the panel will shed light on how early is too early and when is just right to engage.
Attendees will also gain insight into how large pharma teams structure search & evaluation processes, how red flags are interpreted, and what signals strong partnership potential.
Moderated by Jeremy Sohn, Managing Partner at P74 Ventures, this conversation brings together key voices shaping pharma’s external innovation strategy:
 |
 |
 |
| Jeremy SohnManaging Partner P74 Ventures (Moderator) |
Hyelim ChoSenior Director, BD and Alliance Management RayzeBio (a Bristol Myers Squibb company) |
Nikhil MutyalHead of Search and Evaluation, Respiratory and Immunology AstraZeneca |
 |
 |
| Armin RumpDirector of Global Business Development Otsuka Pharmaceutical Co., Ltd. |
Jenny WangDirector, Search & Evaluation, Oncology AbbVie |
These leaders are actively scouting for high-impact innovations and will share how their organizations assess risk, potential, and fit in a rapidly evolving landscape. You will hear how shifting trends are reshaping pharma’s partnering approach, and what startups can do to stand out in a competitive environment.
Whether you are aiming for a strategic investment, licensing deal, or co-development partnership, this panel offers direct access to the minds shaping pharma’s innovation agenda. Founders, BD professionals, and investors alike will walk away with actionable insights into what it takes to get – and stay on – Big Pharma’s radar.
Register today and save with early bird rates.
Next Phase Newsletter 
Leave a comment